Impact of Sars-cov-2 Infection in Waiting List for Liver Transplantation: A Cohort Study on Clinical Outcomes
A. Sessa, A. Mazzola, B. Granger, D. Wakselman, M. Atif, V. Martinez, M. Mallet Maxime, D. Thabut, O. Scatton, F. Conti
Hopital Pitie Salpetriere, Paris, France
Meeting: 2021 American Transplant Congress
Abstract number: 767
Keywords: Infection, Liver, Liver cirrhosis, Morbidity
Topic: Clinical Science » Infectious Disease » All Infections (Excluding Kidney & Viral Hepatitis)
Session Information
Session Name: All Infections (Excluding Kidney & Viral Hepatitis)
Session Type: Poster Abstract
Session Date & Time: None. Available on demand.
Location: Virtual
*Purpose: Infections in cirrhotic patients are associated with an increased risk of liver-related complications (LRC) and mortality. Limited data regarding the prevalence of Coronavirus disease (COVID-19) in cirrhotic patients’ awaiting liver transplantation (LT) are available. The aim of this study was to evaluate the prevalence of Sars-cov2 in a cohort of cirrhotic patients and its impact on LRC rate and on LT.
*Methods: We retrospectively included 187 waitlist patients for LT from 24-January-2020 (2020-cohort) and 123 patients from 24-January-2019 (2019-cohort). All 2020-cohort patients were screened for COVID-19 symptoms with a survey. COVID-19 infection was defined by a positive PCR assay for SARS-CoV-2 on nasopharyngeal swab or the positivity for specific antibodies or typical lung lesions on CT scan. We also assessed the indirect impact of Sars-Cov2 infection on LRC and LT rate, estimated by competitive risk survival analyses in 2020-cohort vs. 2019-cohort (Fine and Gray method).
*Results: In 2020-cohort, 72.7% (n=136) of patients were male with mean age of 55.5±12, 47.2% (n=85) patients have alcohol and/or NASH related cirrhosis, with a median MELD score of 14.1±7.4. 45.5% (n=71), 38.5% (n=60) and 14.8% (n=23) of patients were A, B and C for Child-Pugh-score, respectively. 172 patients responded to survey and 22% (n= 38) had symptoms. 20/38 patients were tested for Sars-Cov2 and 4 patients were positive. 3/4 patients with COVID-19 disease needed hospitalization and 1 intensive care support. No death was reported and 1 patient was LT. The 2020-cohort and 2019-cohort were comparable for sex (p=0,6), age (p=0.7), comorbidities (p=0.2) and Child-Pugh-score (p=0.2). The cumulative incidence of LRC was not significantly higher in the 2020-cohort vs. 2019-cohort (SHR 0.65, 95% CI 0.36-1.15, p=0.138). The cumulative incidence of LT was significantly lower in the 2020-cohort than in the 2019-cohort (SHR0.21, 95% CI 0.13-0.33, p<0.001).
*Conclusions: Our study reported a low prevalence rate of Sars-Cov2 infection in a cohort of cirrhotic patients waiting for LT. No Sars-Cov2 infection direct or indirect impact on mortality and LRC rate was reported. However, a significant shortage of LT was found in 2020 cohort.
To cite this abstract in AMA style:
Sessa A, Mazzola A, Granger B, Wakselman D, Atif M, Martinez V, Maxime MMallet, Thabut D, Scatton O, Conti F. Impact of Sars-cov-2 Infection in Waiting List for Liver Transplantation: A Cohort Study on Clinical Outcomes [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/impact-of-sars-cov-2-infection-in-waiting-list-for-liver-transplantation-a-cohort-study-on-clinical-outcomes/. Accessed May 16, 2025.« Back to 2021 American Transplant Congress